MedPath

Efficacy and Safety of HCP1102 Capsule

Phase 3
Completed
Conditions
Asthma With Allergic Rhinitis
Interventions
Drug: HCP1102+HGP0711Placebo
Drug: HCP1102Placebo+HGP0711
Registration Number
NCT02552667
Lead Sponsor
Hanmi Pharmaceutical Company Limited
Brief Summary

Efficacy and safety of HCP1102 capsule : A randomized, double-blind, active-controlled, multicenter phase 3 clinical trial.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
228
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
HCP1102+HGP0711PlaceboHCP1102+HGP0711PlaceboHCP1102Placebo+HGP0711Placebo(1week) -\> HCP1102+HGP0711Placebo(4weeks) Each 1 capsule, once daily
HCP1102Placebo+HGP0711HCP1102Placebo+HGP0711HCP1102Placebo+HGP0711Placebo(1week) -\> HCP1102Placebo+HGP0711(4weeks) Each 1 capsule, once daily
Primary Outcome Measures
NameTimeMethod
Change of Mean Daytime Nasal Symptom Scorebase line, 3-4week(2weeks)
Secondary Outcome Measures
NameTimeMethod
Change of Runny nose (Mean Daytime Nasal Symptom Score)base line, 1-2week(2weeks), 3-4week(2weeks)
Change of pruritus (Mean Daytime Nasal Symptom Score)base line, 1-2week(2weeks), 3-4week(2weeks)
Change of Mean Nighttime Nasal Symptom Scorebase line, 1-2week(2weeks), 3-4week(2weeks)
Change of Mean Daytime Nasal Symptom Scorebase line, 1-2week(2weeks), 3-4week(2weeks)
Change of Mean Composite Symptom Scorebase line, 1-2week(2weeks), 3-4week(2weeks)
Change of sneezing (Mean Daytime Nasal Symptom Score)base line, 1-2week(2weeks), 3-4week(2weeks)

Trial Locations

Locations (1)

Soon Chun Hyang University Hospital Bucheon

🇰🇷

Bucheon, Gyunggi -do, Korea, Republic of

© Copyright 2025. All Rights Reserved by MedPath